Shinpoong Pharmaceutical Co.,Ltd (019170.KS) Stock
Shinpoong Pharmaceutical Co.,Ltd

Company profile
Shinpoong Pharmaceutical reported revenue of 234.68 billion KRW for fiscal year 2025, up 6.1% from fiscal year 2024. In Q1 2026 (the quarter ended March 31, 2026) revenue was 54.53 billion KRW, down 1.6% from a year before. South Korea was its largest region in fiscal year 2024, with 74% of revenue. In Q1 2026 it reported net income of 358.51 million KRW, against a net loss of 1.28 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 200.23 billion KRW in fiscal year 2023 to 234.68 billion KRW in fiscal year 2025, 8.3% a year on average. Shinpoong Pharmaceutical reports about 656 full-time employees.
What stands out
- It returned to a profit in fiscal year 2025, 8.83 billion KRW, after 4 years of net losses (15.39 billion KRW in fiscal year 2024).
- Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Shinpoong Pharmaceutical Co.,Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products. In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.
Largest shareholders
- Song Am SA24.46%
- Shinpoong Pharmaceutical Co.,Ltd7.08%
- Won-Joon Chang0.1916 %0.19%
- Je-Man Yoo0.0404 %0.04%
- Chung Joo0.003396 %0.00%
Share of the company, as of September 25, 2026
Leadership
- Jei-Man Ryu — CEO & Inside Director, 69
- InIl Jeong — Head of Financial Management Division
- JooYoung Sung — MD & Inside Director, 60
How much revenue does Shinpoong Pharmaceutical make?
Shinpoong Pharmaceutical reported 234.68 billion KRW in revenue for fiscal year 2025, up 6.1% from 221.09 billion KRW in fiscal year 2024. In Q1 2026 revenue was 54.53 billion KRW.
Where does Shinpoong Pharmaceutical make most of its revenue?
South Korea: 74% of revenue by region in fiscal year 2024, followed by Japan (9%).
What companies are similar to Shinpoong Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Boryung Corporation (003850.KS), Daewoong Co., Ltd. (003090.KS), JW Pharmaceutical Corporation (001060.KS), Ildong Pharmaceutical Co., Ltd. (249420.KS).
Has Shinpoong Pharmaceutical made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 11.58 billion KRW; FY2022, a loss of 35.38 billion KRW; FY2023, a loss of 57.33 billion KRW; FY2024, a loss of 15.39 billion KRW; FY2025, 8.83 billion KRW. It reported a net loss in 4 of these 5 years.
How has Shinpoong Pharmaceutical's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 189.24 billion KRW; FY2022, 209.29 billion KRW; FY2023, 200.23 billion KRW; FY2024, 221.09 billion KRW; FY2025, 234.68 billion KRW.
Data as of .
How to cite: DataPorium, “Shinpoong Pharmaceutical Co.,Ltd (019170.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/019170.KS